

Limited Availability of Nirsevimab — Interim CDC Recommendations to Protect Infants from Respiratory Syncytial Virus (RSV)

TVFC Providers,

On Monday, October 23, 2023, the Centers for Disease Control and Prevention (CDC) issued a notice via the [Health Alert Network \(HAN\)](#) recommending health care settings currently experiencing shortages of nirsevimab prioritize available 100mg doses to infants at the highest risk for severe RSV disease. This includes all infants less than six months of age and select groups of older babies who have certain risk factors. Recommendations for 50mg doses of nirsevimab remain unchanged at this time.

We appreciate your support in spreading awareness of this notice and in helping families understand other prevention strategies they can employ to help protect babies from severe RSV illness, including the RSV vaccine that can be given during weeks 32 to 36 of pregnancy and everyday health and hygiene practices like handwashing and staying home when sick.

Thank you for your continued support.

Texas Department of State Health Services

Immunizations Section